Cargando…
ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed...
Autores principales: | Iwanaga, Naoki, Cooper, Laura, Rong, Lijun, Maness, Nicholas J., Beddingfield, Brandon, Qin, Zhongnan, Crabtree, Jackelyn, Tripp, Ralph A., Yang, Haoran, Blair, Robert, Jangra, Sonia, García-Sastre, Adolfo, Schotsaert, Michael, Chandra, Sruti, Robinson, James E., Srivastava, Akhilesh, Rabito, Felix, Qin, Xuebin, Kolls, Jay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686446/ https://www.ncbi.nlm.nih.gov/pubmed/34957381 http://dx.doi.org/10.1016/j.isci.2021.103670 |
Ejemplares similares
-
Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2
por: Iwanaga, Naoki, et al.
Publicado: (2020) -
C57BL/6J Mice Are Not Suitable for Modeling Severe SARS-CoV-2 Beta and Gamma Variant Infection
por: Currey, Joshua M., et al.
Publicado: (2022) -
The virucidal effects of 405 nm visible light on SARS-CoV-2 and influenza A virus
por: Rathnasinghe, Raveen, et al.
Publicado: (2021) -
Endothelial cell infection and dysfunction, immune activation in severe COVID-19
por: Qin, Zhongnan, et al.
Publicado: (2021) -
Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection
por: Han, Kun, et al.
Publicado: (2021)